BeyondSpring Investor Relations Material

BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on the development of innovative cancer therapies. The company’s primary asset is Plinabulin, a selective immunomodulating microtubule-binding agent. Plinabulin is being developed for multiple applications, including as an anti-cancer agent and for the prevention of chemotherapy-induced neutropenia (CIN). BeyondSpring is also exploring the use of Plinabulin in combination with various immuno-oncology agents, chemotherapy, and radiation to treat different cancer types. In addition to Plinabulin, the company is involved in early-stage research through its drug discovery platform and is working on other small molecule immune agents.